A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence

Journal of the National Cancer Institute

Volumn 100, Issue 13, 2008, Pages 967-971

  Asgari, Maryam M ^a,b   Maruti, Sonia S ^a,c,d   White, Emily ^a,c,d  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; SELF REPORT;

ACETAMINOPHEN; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; NORTHWESTERN UNITED STATES; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; VITAMINS;

EID: 46849110150     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn154     Document Type: Article

References (16)

1. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608-615.
2. Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007;99(11):881-889.
3. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80(12):1618-1619.
4. Arber N, Eagle CJ, Spicak J, et al. PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885-895.
5. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6(1):71-73.
6. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97(13):975-980.
7. Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of non-steroidal antiinflammatory drugs and malignant melanoma among women. Oncol Rep. 2001;8(3):655-657.
8. Ramirez CC, Ma F, Federman DG, Kirsner RS. Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg. 2005;31(7 Pt 1):748-752.
9. Ming ME, Shin DB, Bauer JA, Troxel AB. Statins, non-steroidal anti-inflammatory drugs (NSAIDs) and calcium channel blockers are prescribed less frequently for patient who later develop melanoma. Abstract. J Invest Dematol. Symposium Proceedings. 2006;126(suppl 1):49.
10. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets. 2004;4(1):29-42.
11. Kast RE. Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. Med Oncol. 2007;24(1):1-6.
12. Denkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001;61(1):303-308.
13. Goulet AC, Einsphar JG, Alberts DS, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther. 2003;2(6):713-718.
14. White E, Patterson RE, Kristal AR, et al. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol. 2004;159(1):83-93.
15. Lejeune FJ, Monnier Y, Rüegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res. 2006;16(3):263-265.
16. Wilson KS. Clinical activity of celecoxib in metastatic malignant melanoma. Cancer Invest. 2006;24(8):740-746.